Results 181 to 190 of about 114,702 (262)

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). [PDF]

J Clin Oncol
Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM.   +27 more
europepmc   +1 more source

Novel Disubstituted Pyrimidines as Inhibitors of Bruton’s Tyrosine Kinase [PDF]

ACS Medicinal Chemistry Letters, 2014
openaire   +2 more sources

Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft. [PDF]

Front Med (Lausanne)
Stavart L, Halfon M, Dewarrat N, Rotman S, Golshayan D.   +4 more
europepmc   +1 more source

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Blood, 2015
Jennifer R. Brown, J. Barrientos, P. Barr, I. Flinn, J. Burger, A. Tran, F. Clow, D. James, T. Graef, J. Friedberg, K. Rai, S. O'brien   +11 more
semanticscholar   +1 more source

A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.

Journal of dermatological science (Amsterdam), 2021
J. Yamagami, H. Ujiie, Y. Aoyama, N. Ishii, C. Tateishi, A. Ishiko, T. Ichijima, S. Hagihara, K. Hashimoto, M. Amagai   +9 more
semanticscholar   +1 more source

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. [PDF]

Am J Hematol
Cooper N, Jansen AJG, Bird R, Mayer J, Sholzberg M, Tarantino MD, Garg M, Ypma PF, McDonald V, Percy C, Košťál M, Goncalves I, Bogdanov LH, Gernsheimer TB, Diab R, Yao M, Daak A, Kuter DJ.   +17 more
europepmc   +1 more source

Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia [PDF]

, 2018
AG Evans, B Mizukawa, FM Vega, G Pillinger, H Wu, HP Kuo, HS Kuehn, J Wei, K Bence, L Zaitseva, M Konopleva, MA Ayoub, MY Murray, R Schrage, S Tavor, SA Rushworth, SP Xu, T Oellerich, TL Gu   +18 more
core   +1 more source

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor [PDF]

Synfacts, 2018
openaire   +1 more source